Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages.
Saved in:
| Title: | Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages. |
|---|---|
| Authors: | Yehoshua A; Pfizer Inc, New York, USA., Cook AD; Pfizer Inc, New York, USA., Di Fusco M; Pfizer Inc, New York, USA., Rudolph AE; Pfizer Inc, New York, USA., Thoburn E; Pfizer Inc, New York, USA., Lopez SMC; Pfizer Inc, New York, USA., Yarnoff B; Evidera Inc, Bethesda, USA., Andersen KM; Pfizer Inc, New York, USA. |
| Source: | Journal of medical economics [J Med Econ] 2024 Jan-Dec; Vol. 27 (1), pp. 1372-1378. Date of Electronic Publication: 2024 Oct 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1941-837X |
|---|---|
| DOI: | 10.1080/13696998.2024.2416873 |
